SLC31A1 and neoplasm: EGCG can enhance the sensitivity of cisplatin through copper transporter 1 (CTR1) up-regulation, which results in the accumulation of cellular cisplatin and cisplatin–DNA adducts in human ovarian cancer SKOV3 and OVCAR3 cells, and the combination of EGCG and cisplatin suppresses tumor growth in OVCAR3 xenograft mice [122].